Gloucestershire Hospitals NHS Foundation Trust

Population 600,000
Beds 1,060
Income £432,563k
Comprehensive Surplus £6,826k
Operating Surplus £13,285k
PPI Cap 2.1%
PPI £4,779k
Public Members 12,263

In 2011/12 the trust was still under review due to previous breaches to the terms of its authorisation.

The trust website says that the Knightsbridge Ward (15 beds) at Cheltenham General Hospital is used for private patients, and that private patients are also admitted at Gloucester Royal [1] (12 beds).

The trust considers its “competitor” to be Gloucestershire Community Services (the Forward Plan [2] was submitted before more recent decisions were made on the community services).

There are a small number of services, usually community based specialist services, where GCS and GHNHSFT could be viewed as “competitors”. Examples include muscular skeletal interface and treatment services and specialist community respiratory support. The policy direction of care closer to home is likely to increase the areas of potential competition with GCS.

In terms of AQP, the trust takes an optimistic view, even suggesting that it will be a good thing to increase needed capacity:

This transfer of NHS funded work to the independent sector does represent competition for GHNHSFT but much of this activity is in clinical areas where the demand for services is outstripping the capacity within the Trust and where, in the absence of this work, the Trust would have difficulty maintaining its access targets. The focused nature of this work in the independent sector does allow these providers to offer a good patient experience and it is important that the Trust continues to improve its elective care pathways to enable it to match that experience for those patients accessing services through GHNHSFT.

Further, it says:

Prime Diagnostics Limited is a new provider that has entered into a contract with GCS for the use of endoscopy facilities at Stroud and Cirencester hospitals. This again is an area where the Trust has struggled to provide capacity to meet demand and meet access targets so the short-term impact is beneficial. In the longer term the Trust will need to review its position to avoid the loss of income and market share in an clinical area which generates a significant contribution.

Site Map
Up: Trust profiles